A Gel-Based Proteomic Comparison of Human Cerebrospinal Fluid between Inflicted and Non-Inflicted Pediatric Traumatic Brain Injury by Gao, Wei-min et al.
JOURNAL OF NEUROTRAUMA
Volume 24, Number 1, 2007
© Mary Ann Liebert, Inc.
Pp. 43–53
DOI: 10.1089/neu.2006.0061
A Gel-Based Proteomic Comparison of Human Cerebrospinal
Fluid between Inflicted and Non-Inflicted Pediatric 
Traumatic Brain Injury
WEI-MIN GAO,1,4,8 MANDEEP S. CHADHA,1,4 RACHEL P. BERGER,3,5
GILBERT S. OMENN,6 DAVID L. ALLEN,7 MICHAEL PISANO,7 P. DAVID ADELSON,2,5
ROBERT S. B. CLARK,1,3,4,5 LARRY W. JENKINS,2,4 and PATRICK M. KOCHANEK1,3,4,5
ABSTRACT
Traumatic brain injury (TBI) is the most common cause of traumatic death in infancy, and inflicted
TBI (iTBI) is the predominant cause. Like other central nervous system pathologies, TBI changes
the composition of cerebrospinal fluid (CSF), which may represent a unique clinical window on
brain pathophysiology. Proteomic analysis, including two-dimensional (2-D) difference in gel elec-
trophoresis (DIGE) combined with mass spectrometry (MS), was used to compare the CSF protein
profile of two pooled samples from pediatric iTBI (n  13) and non-inflicted TBI (nTBI; n  13)
patients with severe injury. CSF proteins from iTBI and nTBI were fluorescently labeled in tripli-
cate using different fluorescent Cy dyes and separated by 2-D gel electrophoresis. Approximately
250 protein spots were found in CSF, with 90% between-gel reproducibility of the 2-D gel. Follow-
ing in-gel digestion, the tryptic peptides were analyzed by MS for protein identification. The acute
phase reactant, haptoglobin (HP) isoforms, showed an approximate fourfold increase in nTBI ver-
sus iTBI. In contrast, the levels of prostaglandin D2 synthase (PGDS) and cystatin C (CC) were 12-
fold and sevenfold higher in iTBI versus nTBI, respectively. The changes of HP, PGDS, and CC
were confirmed by Western blot. These initial results with conventional gel-based proteomics show
new protein changes that may ultimately help to understand pathophysiological differences between
iTBI and nTBI.
Key words: acute phase response; cerebrospinal fluid; child abuse; haptoglobin; mass spectrometry; shaken
baby syndrome; two-dimensional gel electrophoresis
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INTRODUCTION
TRAUMATIC BRAIN INJURY (TBI) is the most commoncause of morbidity and mortality in childhood, and
inflicted TBI (iTBI) is the most common cause of trau-
matic death in infancy (CDC, 1990; Duhaime et al., 1998;
Adelson and Kochanek, 1998). iTBI, often referred to as
shaken-baby syndrome, is largely restricted to children
under 3 years of age, with the majority of cases occur-
ring during the first year of life (Duhaime et al., 1987).
More than 20% of the head injuries and 80% of all se-
vere TBI deaths in children under 2 years of age are from
iTBI (Duhaime et al., 1992; Goldstein et al., 1993;
Keenan et al., 2003). The intracranial injuries in these in-
fants are characterized by subarachnoid, subdural, and in-
trahemispheric bleeding, frequently with cerebral edema,
followed by progressive cortical atrophy that may con-
tinue after injury (Duhaime et al., 1987; Spaide et al.,
1990). Mortality from iTBI has been estimated to be as
high as 33%, and significant morbidity is seen in over
half of the survivors (Duhaime et al., 1987; Spaide et al.,
1990).
Due to the uncertainty of diagnosing child abuse and
the lack of sensitive or specific signs, symptoms, or ob-
jective biochemical evidence, the detection of iTBI can
be difficult (Jenny et al., 1999). Previous studies sug-
gested that the biochemical response of the brain to iTBI
is different from non-inflicted TBI (nTBI) (Bell et al.,
1999; Berger et al., 2004a,b; Clark et al., 2000; Ruppel
et al., 2001; Whalen et al., 1998, 2000; Lai et al., 2004;
Satchell et al., 2005). For example, cerebrospinal fluid
(CSF) concentrations of glutamate (Ruppel et al., 2001),
quinolinic acid (Bell et al., 1999; Berger et al., 2004a),
P-selectin (Whalen et al., 1998), interleukin-8 (Whalen
et al., 2000), Hsp70 (Lai et al., 2004), and cytochrome c
(Satchell et al., 2005) were significantly higher after iTBI
versus nTBI, while the concentration of the endogenous
neuroprotectant bcl-2 in CSF was lower (Clark et al.,
2000). Because of the complexity of the brain, finding a
single biochemical identifier that is both sensitive and
specific for iTBI is unlikely; therefore, an approach to
develop a panel of biochemical identifiers as a potential
screening tool or diagnostic adjunct for iTBI versus nTBI
seems more realistic. Thus, proteomics has the potential
to provide additional insights. Proteomic technologies al-
low the simultaneous analysis of a large number of pro-
teins and can be used to characterize different patho-
physiological conditions (Hochstrasser et al., 2002). The
most classic proteomic approach includes protein sepa-
ration by two-dimensional (2-D) gel electrophoresis, and
protein identification by mass spectrometry (MS) (Free-
man and Hemby, 2004; Rohlff, 2000). iTBI and nTBI,
like other central nervous system (CNS) pathologies,
cause changes in the composition of CSF. Consequently,
analysis of the CSF protein components may help iden-
tify or confirm pathological processes involved in iTBI,
and generate an increasing number of injury-specific can-
didate proteins that can be utilized more specifically for
diagnostics, prognostics, and pathophysiology. To date,
only one clinical CSF 2-D gel based proteomic study has
been done in adult TBI (Conti et al., 2004), but none in
pediatric patients. The aim of this study was to compare
CSF proteins between iTBI and nTBI using 2-D differ-
ence in gel electrophoresis (DIGE) coupled with MS
analysis.
METHODS
Patients and Cerebrospinal Fluid Samples
This study was approved by the Institutional Review
Board of the University of Pittsburgh, and informed con-
sent was obtained from parents for sample collection. All
patients were admitted to the Pediatric Intensive Care
Unit at the Children Hospital of Pittsburgh. iTBI from
child abuse was diagnosed by the Children Hospital of
Pittsburgh Child Protection Team. All CSF samples were
part of a repository at the Safar Center for Resuscitation
Research/Children Hospital of Pittsburgh, and were pre-
viously collected from infants and children with severe
TBI. Ventricular CSF drainage is part of standard neu-
rointensive care for our institution (Bell et al., 1999; Clark
et al., 2000; Ruppel et al., 2001; Lai et al., 2004; Berger
et al., 2002). All samples were stored at 80°C. Clini-
cal data collected included demographic information,
mechanism of injury, Glasgow Coma Scale (GCS) score
at presentation, results of initial cranial computed to-
mography (CT), and survival status. We evaluated CSF
samples in this repository specifically from infants and
children 4 years old and with CSF samples collected
within the first 24 h of hospital admission. Based on these
two criteria, CSF was available from 26 patients, 13 pa-
tients from each of iTBI and nTBI. A sample of 200 L
of CSF from each of these patients was placed in two
separate pools.
Two-Dimensional DIGE
Sample labeling. Approximately 600 L of pooled
CSF from iTBI and nTBI were concentrated to 100 L
by using Centricon (YM-3, Amicon Bioseparations)
tubes, at 6,000 rpm at 4°C for 2.5 h. Protein content 
was measured using a Bradford assay (BioRad). Con-
centrated CSF samples from nTBI and iTBI were labeled
in triplicate with Cy3-N-hydroxysuccinimide ester (Cy3)
and Cy5-N-hydroxysuccinimide ester (Cy5), respectively
(Amersham Biosciences, Piscataway, NJ). Briefly, 100
g of each sample was transferred to an Eppendorf tube
and placed on ice. Lysis buffer containing 30 mM Tris,
pH 8.5 (titrated with dilute HCl on ice), 8 M urea, and
4% CHAPS was added to adjust the protein concentra-
tion to 5 g/L. Each Cy dye was diluted 5 times with
N,N-dimethylformamide (DMF), and 1 L of diluted Cy3
and Cy5 were added to the pooled CSF samples of nTBI
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and iTBI, respectively. After centrifugation, tubes were
placed on ice for 30 min without light exposure, and 1
L of 10 mM lysine was added to stop the reaction. Fol-
lowing sample centrifugation, the mixture was kept on
ice for 10 min without excess light exposure. Final sam-
ple volume was adjusted to 500 L by adding 2-D re-
hydration buffer (BioRad).
Two-dimensional gel electrophoresis. After overnight
rehydration of 17-cm immobilized linear pH 3–10 gradi-
ent (IPG) strips (BioRad), focusing occurred with 500 V
for 30 min and 10,000 V for 3 h for a total of 30,000 Vh.
IPG strips were equilibrated with equilibration buffer I
and buffer II (BioRad), and separated with sodium do-
decyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) using 11–14% gradient Tris-HCl gels.
Image analysis. The gels were fixed with 50%
methanol and 5% acetic acid, and viewed using a Ty-
phoon 9400 Imager (Amersham). Imaging was per-
formed at two excitation wavelengths, 532 and 633 nm
for Cy3 and Cy5, respectively. Image manipulation and
viewing was done with Image Quant software (Amer-
sham). Sample-dependent differences in protein distri-
butions were confirmed and quantified using BioImage
2-D Analyzer software (version 6.3; Genomic Solutions,
Inc.), on an Ultra 5 Sun workstation to locate and mea-
sure protein spot intensity as well as match spots between
gel pairs (Jenkins et al., 2002). Spot matching was done
by automated spot matching via a constellation matching
algorithm. The normalization-of-gel pairs were derived
from the sum of integrated intensities of all matched spots
that appeared on both pairwise compared gels (match ra-
tio). Individual differences in intensity were calculated
for each spot on every pair of gels.
In-Gel Enzyme Digestion and Protein
Identification by Mass Spectrometry
Selected gel protein spots between the iTBI and nTBI
were harvested from the 2-D gels stained by a modified
silver staining method, digested with trypsin, and sub-
mitted for MS analysis (Proteomic Research Services,
Ann Arbor, MI).
In-gel digestion. Samples were subjected to proteolytic
digestion on a GSI ProGest™ workstation. Gel plugs
were swollen and dessicated with alternate additions of
100% acetonitrile and 25 mM ammonium bicarbonate.
Gel plugs were subsequently reduced with 10 mM dithio-
threitol (DTT) and alkylated with 100 mM iodoac-
etamide. Samples were trypsinized at 37°C for 4 h
(Promega sequencing grade modified trypsin) and halted
with the addition of 3% formic acid.
MALDI mass spectrometry. A portion of the resulting
Digest supernatant was then used for matrix-assisted laser
desorption/ionization (MALDI) MS analysis. Samples
were spotted onto a MALDI target robotically (ProMS)
using ZipTips (Millipore, Bedford, MA). Peptides were
eluted from the C18 (ZipTip) material with a matrix 
(-cyano 4-hydroxy cinnamic acid) prepared in 60% ace-
tonitrile, 0.2% trifluoroacetic acid (TFA). MALDI/MS
data was acquired on an Applied Biosystems Voyager
DE-STR instrument. The observed m/z values were sub-
mitted to a ProFound software package (Proteometrics).
ProFound queried a locally stored copy of the NCBInr
database for peptide mass fingerprint searching.
LC-MS/MS. Samples were analyzed by nanoflow cap-
illary liquid chromatography (LC)–tandem mass spec-
trometry (MS/MS) on an electrospray quadrupole–time
of flight (Q-TOF) (MicroMass, Manchester, UK). Fast-
gradient nanoscale LC-MS/MS was utilized for the analy-
sis of in-gel digests. Briefly, 15 L of hydrolysate were
processed on a 15 cm  75 m C18 column at a flow-
rate of 200 nL/min online with a Q-TOF 2. MS/MS data
were searched with MASCOT (Matrix Science, Ltd.,
Boston, MA) for tryptic peptides. The MASCOT search
parameters included (a) all kingdoms, (b) tolerance of
one missed trypsin cleavage per protein, and (c) fixed
protein modification  carbamidomethylation (C). Vari-
able tolerances include (a) oxidation of methionine, (b)
amino termini conversion of glutamine to pyro-glutamate
as well as amino acetylation), (c) mass values of mono-
isotopic unrestricted protein mass, and (d) peptide mass
tolerance of 100 ppm and fragment mass tolerance of 0.1
Da. Searches were against the NCBInr database. The pro-
tein identification criteria are (1) at least two high scor-
ing (Mascot scores of 30 with “validated” spectra) pep-
tides must match to each protein, and (2) in each of those
spectra, the abundant fragment ions must be assigned.
Immunoblotting Analysis for Haptoglobin (HP),
Prostaglandin D2 Synthase (PGDS), 
and Cystatin C (CC)
Pooled CSF levels of HP, PGDS, and CC as well as
CC in individual CSF samples from iTBI and nTBI pa-
tients were further independently verified with Western
blots. Briefly, 10 L of CSF protein was separated by
SDS-PAGE. Then the resolved proteins were transferred
to the polyvinylidene difluoride (PVDF) membrane (Mil-
lipore, Bedford, MA). Following incubation in blocking
buffer (0.1% Tween 20 in PBS [PBST0.1] containing 2%
nonfat dry milk [BioRad]) for 2 h, the membrane was hy-
bridized in blocking buffer containing either anti-HP
chicken IgY polyclonal antibody at 0.2 g/mL (Abcam
GEL-BASED CSF PROTEOMICS OF PEDIATRIC TBI
45
Inc, Cambridge, MA), anti-PGDS rabbit immunoglobu-
lin G (IgG) polyclonal antibody at 0.025 g/mL (Dade
Behring, Marburg, Germany), or anti-CC rabbit IgG
polyclonal antibody at 0.05 g/mL (Upstate Biotechnol-
ogy, Lake Placid, NY) for 1 h. The membrane was then
washed and incubated with a horseradish peroxidase–
conjugated donkey anti-rabbit IgG (Amersham) or rabbit
anti-chicken (Abcam) secondary antibodies at a 1:2000
dilution for 1 h. After washing, the membrane was incu-
bated in ECL (Enhanced Chemiluminescence, Amer-
sham) for 1 min, then exposed to imaging films.
Statistical Analysis
The images were quantified using BioImage 2-D An-
alyzer software. The Mann-Whitney test was performed
to compare individual samples between iTBI and nTBI.
RESULTS
Patients
The clinical and demographic information of the sub-
jects are listed in Table 1. Patients were selected based
on age of 4 years. Children with iTBI (age 0.81  1.15)
were younger than those of nTBI (age 2.37  1.22; p 
0.01). Female patients were more predominant in iTBI
than that of nTBI (p  0.05). There was no difference in
admission Glasgow Coma Scale (GCS) score between
iTBI and nTBI patients. The etiology of injury for the 13
children with nTBI included five motor vehicle collisions
(MVC), five falls, and three other causes. The etiology
of injury for the children with iTBI was unknown. There
were also no remarkable differences in the CT scan find-
ings between iTBI and nTBI groups.
DIGE analysis
Approximately 250 protein spots were identified in the
pooled CSF sample. Triplicate DIGE gels were run and
showed more than 90% between-gel reproducibility. Im-
age analysis of fluorescently labeled paired CSF samples
loaded together on 2-D gels identified different protein
distributions in iTBI compared to nTBI. A representative
DIGE gel is shown Figure 1. Comparisons between pair-
wise iTBI and nTBI gels matched a mean of 92% (230
spots). From these matched spots, a mean of 60 spots had
a twofold, 21 spots had a threefold, and four spots had
more than a sixfold increase or decrease in protein level
in iTBI versus nTBI. Using stringent criteria in order to
consider protein spots, only differences of more than
threefold changes and those that were present in all trip-
licate gels were considered biologically relevant. In ad-
dition to spots that were successfully identified, five spots
from iTBI pooled samples and four spots from nTBI
pooled samples were novel but had insufficient protein
abundance to be identified by MS.
Protein Identification by Mass Spectrometry
Proteins with higher levels in nTBI versus iTBI. For
the four spots identified as HP or HP precursor, there
were six (12% sequence coverage), nine (15% sequence
coverage), 12 (19% sequence coverage), and 24 (50% se-
quence coverage) matched peptides from the LC-MS/MS
with a total score of 177, 296, 213, and 671 (Fig. 2A),
respectively. Comparison with human CSF 2-D reference
maps allowed the unambiguous identification of the iso-
forms of HP as HP, HP1, and HP2, respectively, as
labeled in Figure 1. In addition, HP, HP1, and HP2
showed 10, two, and three different oligosaccharide iso-
forms as individual spots in the 2-D gels (Fig. 1). All
these isoforms were included in the analysis. HP, HP1,
and HP2 showed an average fourfold, fivefold, and
threefold increase, respectively, in nTBI versus iTBI pa-
tients.
Proteins with higher levels in iTBI versus nTBI. Com-
pared to the protein expression in nTBI patients, the sig-
nals for two proteins and their isoforms (Fig. 1), identi-
fied as PGDS (Fig. 2B) and CC (Fig. 2C) with eight and
two different isoform spots by comparing to the 2-D ref-
erence maps, showed an average 12-fold and sevenfold
increase in iTBI versus nTBI, respectively. There were
six (27% sequence coverage) and 13 (70% sequence cov-
erage) matched peptides for PGDS and CC with a total
score of 208 and 332, respectively.
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TABLE 1. CLINICAL AND DEMOGRAPHIC
INFORMATION OF THE PATIENTS




Age (mean  SD, years) 0.81  1.15 2.37  1.22






iTBI, inflicted traumatic brain injury; nTBI, non-inflicted
traumatic brain injury; GCS, Glasgow Coma Scale; CT, com-
puted tomography; IVH, intraventricular hemorrhage; SAH,
subarachnoid hemorrhage; SDH, subdural hemorrhage.
Immunoblotting Analysis of HP, PGDS, and CC
To confirm and validate the results of 2-D DIGE,
Western blot analyses were performed for HP, PGDS,
and CC in pooled iTBI and nTBI CSF samples using
polyclonal antibodies (Fig. 3A–C). In addition, separate
Western blot of CC was run for the 26 individual CSF
samples from 13 iTBI and 13 nTBI patients (Fig. 3D).
The polyclonal antibody for HP identified different iso-
forms—presumably including HP, HP1, and HP2
based on their molecular weight (Fig. 3A). HP and
HP2 had about two- and threefold increases in nTBI
versus iTBI, whereas HP1 was only detectable in nTBI.
As shown in Figure 3B,C, SDS-PAGE showed that the
expression levels of PGDS and CC in the pooled iTBI
were seven- and threefold higher than those of nTBI pa-
tients. Furthermore, as shown in Figure 3D, CSF West-
ern blots from individual samples also showed that the
CC level from iTBI patients were higher than that from
nTBI patients (Mann-Whitney test, p  0.05). The CSF
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FIG. 1. A representative composite difference in gel electrophoresis (DIGE) of inflicted traumatic brain injury (iTBI) and non-
inflicted traumatic brain injury (nTBI). Cerebrospinal fluid (CSF) samples from iTBI and nTBI were labeled with Cy5 (red) and
Cy3 (green), respectively. Yellow spots mean that the protein levels were not different in the two samples. Red spots mean that
the protein levels were higher in iTBI, and the green spots mean that the protein levels were higher in nTBI. HP, haptoglobin;
PGDS, prostaglandin D2 synthase; CC, cystatin C. All the proteins were identified by liquid chromatography–tandem mass spec-
trometry (LC-MS/MS).
from six patients with iTBI had much higher levels of
CC compared to the CSF from 13 patients with nTBI.
DISCUSSION
This initial study using a conventional gel-based pro-
teomic approach provides new protein differences be-
tween iTBI and nTBI. First, changes in HP isoforms, a
protein important in the acute phase response to TBI,
were higher in nTBI, suggesting a blunted acute phase
response in iTBI. This evidence is consistent with the rec-
ognized clinical findings of delayed presentation and/or
multiple chronic injuries potentially blunting the acute
phase response in many iTBI victims (Gilliland, 1998).
Second, protein expression profile comparisons revealed
markedly decreased levels of two additional CSF proteins
in nTBI, identified as PGDS and CC. About 250 protein
spots were identified in the pooled CSF samples, which
showed more than 90% between-gel spot matching. Thus,
our 2-D gel analysis achieved a high level of within-sam-
ple and between-sample reproducibility. Similar changes
were also found in DIGE analysis for each of the two
pooled samples after human serum albumin (HSA) and
gamma globulin (IgG) were removed (data not shown).
Significant differences of CSF HP, PGDS, and CC ex-
pression between iTBI and nTBI were confirmed by one-
dimensional (1-D) SDS-PAGE Western blot. Differences
of these proteins after iTBI and nTBI were not related to
differences in CSF sample protein concentration or post-
injury drainage duration (data not shown).
Our prior studies suggest that CSF changes of several
individual biochemical makers provide clinical insight
into injury, including glutamate (Ruppel et al., 2001),
quinolinic acid (Bell et al., 1997; Berger et al., 2004a),
P-selectin (Whalen et al., 1998), interleukin-8 (Whalen
et al., 2000), Hsp70 (Lai et al., 2004), cytochrome-C
(Satchell et al., 2005), and bcl-2 (Clark et al., 2000).
Changes in CSF from iTBI victims of several of these
molecules suggest a unique pattern of chronic and/or
repetitive injury. For example, quinolinic acid, a marker
of chronic inflammation, is seen in the CSF of some iTBI
victims at initial hospital presentation (Bell et al., 1999).
Similarly, remarkable low levels of the anti-apoptotic
protein bcl-2 (Clark et al., 2000; Satchell et al., 2005)
and high levels of the pro-apoptotic protein cytochrome-
C (Satchell et al., 2005) are seen in CSF of iTBI victims,
as is a delayed increase in CSF level of neuron-specific
enolase Berger et al., 2002), suggesting the possibility of
enhanced apoptotic neuronal death in victims of iTBI ver-
sus nTBI.
Haptoglobin and Traumatic Brain Injury
The acute phase response is a biological response to
systemic or local tissue injury mediated by cytokine stim-
ulation of hepatocyte production of acute phase proteins
providing a defense response to injury. HP is a type 2
acute phase response protein made by hepatocytes as part
of the systemic response to cytokines (i.e., IL-1, IL-6, IL-
8, and TNF) from tissue injury (Campbell et al., 2005;
Petersen et al., 2004; Wilcockson et al., 2002). Type 2
acute phase proteins are activated by IL-6 and negatively
modulated by IL-1 (Petersen et al., 2004). HP also func-
tions as an antioxidant by binding free hemoglobin. In
adult humans, HP proteins can increase 2–10-fold during
a typical acute phase reaction (Petersen et al., 2004).
Thus, CSF HP proteins are likely derived from the gra-
dient between serum and CSF levels. HP isoforms
showed notable increases in nTBI versus iTBI, suggest-
ing possible delayed presentation and/or chronic injury
in iTBI victims. Increases in HP in TBI are likely related
to the previously reported high level of IL-6 and IL-8
(Amick et al., 2001; Bell et al., 1997), which peak dur-
ing the first 24 h (Bell et al., 1997). HP is an antioxidant
(Campbell et al., 2005) and may be a injury-induced neu-
roprotective compensatory mechanism (Vejda et al.,
2002). Alternatively and more likely, increased CSF HP
may simply result from increased blood–brain barrier
(BBB) breakdown or hemorrhage after iTBI versus nTBI,
allowing more movement of HP into the CSF since the
source of HP in CSF after TBI is likely from serum rather
than the brain parenchyma.
PGDS and Traumatic Brain Injury
PGDS and CC are synthesized by the choroid plexus
(Zheng et al., 2003) and are normally found at higher
concentrations in the CSF than plasma (Aldred et al.,
1995). However, these proteins also occur in CNS tissue
and CSF levels can be influenced by brain tissue levels.
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FIG. 2. Tandem mass spectrometry identification of haptoglobin (HP; A), prostaglandin D2 synthase (PGDS; B), and cystatin
C (CC; C). Analysis of the tryptic peptides with electrospray quadrupole–time of flight (Q-TOF), coupled with nanoflow capil-
lary high-pressure liquid chromatography (HPLC). The tandem mass spectrometry fragmentation spectra (obtained after trypsin
digestion) of VGYVSGWGR for HP, GPGEDFR for PGDS, and GGPMDASVEEEGVR for CC are shown. There were 24, 6,
and 13 matched peptides from the liquid chromatography–tandem mass spectrometry (LC-MS/MS) for HP, PGDS, and CC, with
total scores of 671, 208, and 332, respectively. The resultant MS/MS data were searched using MASCOT.







FIG. 3. Immunoblotting analyses for haptoglobin (HP; A),
prostaglandin D2 synthase (PGDS; B), and cystatin C (CC; C)
in pooled inflicted traumatic brain injury (iTBI) and non-in-
flicted traumatic brain injury (nTBI) cerebrospinal fluid (CSF),
and CC (D) in the 26 individual CSF from 13 iTBI and 13 nTBI
patients. In parts A–C, both sodium dodecyl sulfate–polyacry-
lamide gel electrophoresis (SDS-PAGE) image and quantifica-
tion of the bands using BioImage were shown; in part D, only





PGDS represents 3% of the total CSF protein (Clausen,
1961). PGDS is localized in oligodendrocytes (Urade et
al., 1993) and is detected in immature neurons (Urade et
al., 1987). PGDS catalyzes biosynthesis of PGD2 (a ma-
jor neuromodulator prostanoid in the CNS) and serves as
a transport protein for lipophilic substances into the brain
(Urade and Hayaishi, 2000; Urade et al., 2004). Circu-
lating PGDS plays a major physiological role in sleep,
state of consciousness, and arousal (Urade et al., 2004).
PGDS was markedly lower in patients with nTBI versus
iTBI. Decreases in PGDS may diminish the unfolded pro-
tein stress response during nTBI compared to iTBI and
increase the vulnerability of the brain to oxidative stress
cascades (Odani et al., 1996). Changes in CSF PGDS
concentrations may also contribute to different states of
consciousness between iTBI and nTBI.
Cystatin C and Traumatic Brain Injury
CC is a low molecular weight (13 kDa) protein pre-
sent in CSF at high concentration (Abrahamson et al.,
1986). Although CC is mainly found in the extracellular
space and CSF, intracellular localization in astrocytes and
neurons has also been reported (Pierre and Mellman,
1998). CC is an endogenous inhibitor of the cysteine pro-
teases (including cathepsin B, L, H, and S), which are im-
plicated in degradation of cellular proteins and thus may
provide protection against a form of cell death known as
autophagy that involves cathepsins and is prominent dur-
ing development (Ohsumi and Mizushima, 2004). Cathep-
sin B release from microglia activates caspase-3, result-
ing in neuronal apoptosis (Kingham and Pocock, 2001),
which may also be inhibited by CC. However, like many
other CNS proteins that can serve a neuroprotective role,
CC may also have detrimental actions (Olsson et al.,
2004). Decreased CSF CC level was found in nTBI ver-
sus iTBI and may reduce the resistance to neural and/or
glial cell death cascades and/or increased proteolysis af-
ter nTBI. However, we cannot exclude an effect of age
between the two groups (Fliser and Ritz, 2001).
Methodological Approach 
and Technical Limitations
Normalization of CSF protein samples for semi-quan-
titative comparisons is always problematic as a number
of assumptions must be made. If one group had higher
CSF protein levels due to more tissue destruction and he-
morrhage, normalization by total protein concentration
could unequally influence the magnitude of individual
protein levels. Conversely, it was not straightforward to
normalize by CSF volume since ventricular drainage was
used in TBI patients to collect CSF. Thus, we normal-
ized samples using both methods (matched protein con-
centration in 2-D gel and CSF volume in Western blot).
Although there were some differences in the magnitude
but not direction of the results depending on the nor-
malization method used, both showed similar agreement
in HP, PGDS, and CC with similar directional large
changes in iTBI versus nTBI.
Our CSF protein study using a gel-based proteomic
analysis should be complemented by methods that allow
the identification of low-copy and hydrophobic proteins
such as protein arrays and multi-antibody blots (Power-
Blot) (Wang et al., 2004). We chose to limit our initial
study to the first 24 h after injury, but a sequential time
course study is warranted. Due to difficulties in obtain-
ing matched CSF samples from identical clinical popu-
lations, our patients had age and gender discrepancies be-
tween groups. Despite such confounders, the CSF
samples from 26 infants and very young children with
severe iTBI and nTBI represent a unique and extremely
valuable resource and to our knowledge represent the
largest CSF repository of iTBI patients available.
In summary, we report a difference in several high-
copy proteins in CSF from children with iTBI versus
nTBI. Most notably, acute phase proteins such as HP are
low in iTBI, which may suggest a delayed presentation
or chronic injury. Future studies both in experimental
models and clinical TBI will be necessary to elucidate
the pathophysiological role of these protein changes. Fi-
nally, other proteomic approaches should be employed to
compare low abundant and/or hydrophobic protein pro-
files in CSF from iTBI and nTBI subjects.
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